B. Riley Upgrades Cytori Therapeutics (CYTX) to Buy

B. Riley upgraded shares of Cytori Therapeutics (NASDAQ:CYTX) from a neutral rating to a buy rating in a research report sent to investors on Friday, March 9th. B. Riley also issued estimates for Cytori Therapeutics’ Q4 2017 earnings at ($0.10) EPS, FY2017 earnings at ($0.68) EPS, Q1 2018 earnings at ($0.06) EPS, Q2 2018 earnings at ($0.06) EPS and FY2018 earnings at ($0.18) EPS.

CYTX has been the subject of several other research reports. Zacks Investment Research lowered Cytori Therapeutics from a hold rating to a sell rating in a research report on Thursday, November 9th. Maxim Group set a $2.00 price target on Cytori Therapeutics and gave the stock a buy rating in a research note on Friday, March 9th. Laidlaw reiterated a buy rating and set a $1.65 target price on shares of Cytori Therapeutics in a research note on Thursday, February 22nd. Finally, ValuEngine upgraded Cytori Therapeutics from a strong sell rating to a sell rating in a research note on Friday, February 2nd. Two investment analysts have rated the stock with a sell rating and three have issued a buy rating to the company. The stock has an average rating of Hold and a consensus target price of $1.80.

How to Become a New Pot Stock Millionaire

Cytori Therapeutics stock remained flat at $$0.29 during midday trading on Friday. The company had a trading volume of 329,625 shares, compared to its average volume of 1,582,854. Cytori Therapeutics has a twelve month low of $0.22 and a twelve month high of $2.08. The stock has a market capitalization of $17.65, a PE ratio of -0.45 and a beta of 3.13.

Cytori Therapeutics (NASDAQ:CYTX) last released its earnings results on Thursday, March 8th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). The company had revenue of $1.50 million during the quarter, compared to the consensus estimate of $2.00 million. Cytori Therapeutics had a negative net margin of 418.36% and a negative return on equity of 210.47%. equities analysts anticipate that Cytori Therapeutics will post -0.18 EPS for the current fiscal year.

In related news, major shareholder Ag Postfinance sold 236,155 shares of Cytori Therapeutics stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $0.34, for a total value of $80,292.70. Following the completion of the transaction, the insider now owns 5,311,451 shares in the company, valued at $1,805,893.34. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Bank Sa Swissquote sold 100,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $0.38, for a total value of $38,000.00. Following the transaction, the insider now owns 5,496,655 shares of the company’s stock, valued at approximately $2,088,728.90. The disclosure for this sale can be found here. Over the last three months, insiders have sold 695,767 shares of company stock worth $231,951. Insiders own 1.90% of the company’s stock.

An institutional investor recently raised its position in Cytori Therapeutics stock. Perkins Capital Management Inc. increased its stake in shares of Cytori Therapeutics Inc (NASDAQ:CYTX) by 134.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,136,041 shares of the biotechnology company’s stock after buying an additional 1,223,046 shares during the quarter. Perkins Capital Management Inc. owned about 6.08% of Cytori Therapeutics worth $644,000 as of its most recent SEC filing. Institutional investors and hedge funds own 6.21% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “B. Riley Upgrades Cytori Therapeutics (CYTX) to Buy” was originally published by Enterprise Leader and is the property of of Enterprise Leader. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://theenterpriseleader.com/2018/04/02/cytori-therapeutics-cytx-lifted-to-buy-at-b-riley.html.

Cytori Therapeutics Company Profile

Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.

Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply